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Snapshot Dx Quiz 
QUESTIONS
1. What is your diagnosis?
 a. Solar lentigo.
 b. Benign nevus.
 c. Seborrheic keratosis.
 d. Malignant melanoma.
 e. Pigmented squamous cell carcinoma.
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Questions relate to the image as well as to selected articles in JID, which are listed after 
the questions. Answers will be posted as supplementary material. We hope you enjoy 
this challenge.
2. Which of the following statements is false regarding the current treatment options for metastatic melanoma? 
 a. Combination therapy with BRAF and MEK inhibitors demonstrates longer progression-free survival compared 
 to monotherapy with BRAF inhibitor in BRAFV600E-positive melanomas.
 b. Ipilimumab is a humanized monoclonal antibody that stimulates the T-cell response against melanomas by 
 targeting cytotoxic T-lymphocyte-associated protein 4.
 c. The response rate with ipilimumab is generally higher than that achieved with therapies targeting the 
 BRAF/MAPK/ERK pathway.
 d. An important side effect of BRAF inhibitors is accelerated growth of cutaneous squamous-cell carcinomas 
 and keratoacanthomas through paradoxical activation of MAPK signaling.
 e. Pembrolizumab is a humanized monoclonal antibody that targets human programmed death receptor-1.
3. Based on the article by Mukherjee et al., which of the following statements is TRUE regarding the BCL-2 family?
 a. The BCL-2 family consists only of antiapoptotic proteins. 
 b. Dysregulation of the BCL-2 proteins contributes to development of therapeutic resistance to available 
 melanoma treatments.
 c. Decreased expression of MCL-1, an antiapoptotic molecule, is involved in the pathogenesis of melanoma.
 d. Targeting a single BCL-2 protein is sufficient to kill melanoma.
 e. Combination therapy targeting multiple BCL-2 antiapoptotic proteins and retinoid derivative induces 
 cell death only in melanoma stem cells. 
TOPIC ARTICLE
Questions 2 and 3 refer to the following article:
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